The US FDA has approved, on Monday Pembrolizumab in combination with carboplatin and paclitaxel, followed by pembrolizumab as a single agent, to treat adult patients with primary, advanced or recurrent endometrial carcinoma.
The approval came after considering data from the phase 3 NRG-GY018 trial (NCT03914612). During tests, it was found that the Pembrolizumab combination reduced disease progression or death compared with Pembrolizumab administered alone.
Endometrial cancer is believed to be the most common gynaecologic cancer in the US. The anti-programmed death receptor-1 (PD-1) therapy works by increasing the immune system's ability to detect and fight tumour cells.
Inify Laboratories expands to UK, enters gastrointestinal diagnostics
Eli Lilly's Kisunla gains UK marketing authorisation for alzheimer's treatment
TC BioPharm agrees research planning collaboration to develop Monkeypox treatment
Grifols partners with BARDA to develop treatment for sulfur mustard eye injury
Swedish AI Medical Technologies to begin trial for AI melanoma diagnostic tool
Adcentrx Therapeutics' ADRX-0405 IND application approved by US FDA
HELP Therapeutics' HiCM-188 IND application receives US FDA approval
Trevi Therapeutics finishes enrollment in RCC Phase 2a trial
REGENXBIO reveals positive data for ABBV-RGX-314 in bilateral wet AMD